# Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

Source: https://onco.cc/trials/nct07126158/  
OnCo record `nct07126158` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of avutometinib + defactinib in pancreatic cancer, run by Washington University School of Medicine, now recruiting.

## Summary

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma is a phase 2, randomised interventional study registered as NCT07126158 by Washington University School of Medicine, with a registry enrolment figure of 36 participants, started 2026-04-10 and due to reach its primary completion in 2030-04-30. Interventions recorded: Stereotactic body radiotherapy; Defactinib; Avutometinib. Conditions listed: Pancreatic Adenocarcinoma; Cancer of the Pancreas; Pancreas Cancer; Pancreatic Cancer. Primary outcome: Progression-free survival (PFS) - Experimental Arm Only. Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed advanced pancreatic adenocarcinoma that is considered borderline resectable or locally advanced per institutional standardized criteria of unresectability or medical inoperability (NCCN guidelines 2". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07126158
- Phase: 2
- Setting: Phase II Study of Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
- Sponsor: Washington University School of Medicine
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT07126158: https://clinicaltrials.gov/study/NCT07126158

## Connected records

- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- drugs: [Avutometinib + defactinib](https://onco.cc/drugs/avutometinib-defactinib/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07126158.json